Céline Ferlay

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Oral cavity and oropharyngeal squamous cell carcinoma—an update

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Pexidartinib: First Approval

Platelet factor 4–induced T _H 1-T _reg polarization suppresses antitumor immunity

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

Manganese Porphyrin, MnTE-2-PyP5+, Acts as a Pro-Oxidant to Potentiate Glucocorticoid-Induced Apoptosis in Lymphoma Cells

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

Macrophages in immunoregulation and therapeutics

Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

A systematic review of trismus induced by cancer therapies in head and neck cancer patients

A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma

A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Primary brain tumours in adults

EAU Guidelines on Renal Cell Carcinoma: 2014 Update

Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

Cancer-related inflammation and treatment effectiveness

Renal cell carcinoma

Clinical relevance of tumour-associated macrophages

Systemic Therapy for Metastatic Renal-Cell Carcinoma

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade

Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges

Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents

Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics

The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.

Targeted therapy for advanced renal cell carcinoma

Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial

Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA)

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)

Exclusive brachytherapy for T1 and T2 squamous cell carcinomas of the velotonsillar area: Results in 44 patients

Combination of rituximab with chemotherapy in diffuse large B‐cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.